

HEDIS^{®1} for Measurement Years 2020 & 2021 Healthcare Effectiveness Data and Information Set

*Measures collected with medical record review.

Red= new/addition to measures

Blue= Medicare only

New Measures	
Measure	Screening, test or care needed
Cardiac Rehabilitation 18 years and older <u>CPT codes:</u> 93797-93798	<ul style="list-style-type: none"> Attended cardiac rehabilitation following a qualifying cardiac event (myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement). <p>Four rates are reported:</p> <ul style="list-style-type: none"> Initiation: percentage of members who attended 2 or more sessions of cardiac rehabilitation within 30 days after a qualifying event. Engagement 1: percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event. Engagement 2: percentage of members who attended 24 or more sessions of cardiac rehabilitation within 180 days after a qualifying event Achievement: percentage of members who attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event
Kidney Health Evaluation for Patients with Diabetes Adults ages 18-85 <u>CPT codes:</u> eGFR: 80047-80048; 80050; 80053; 80069; 82565 uACR: 82043; 82570	<ul style="list-style-type: none"> Diagnosis of diabetes (type 1 and type 2) Received a kidney health evaluation, defined by: <ul style="list-style-type: none"> an estimated glomerular filtration rate (eGFR) <u>and</u> A urine albumin-creatinine ratio (uACR) <p>Exclusions:</p> <ul style="list-style-type: none"> ESRD Dialysis
Osteoporosis Screening in Older Women Women ages 65-75 <u>CPT codes:</u> 76977; 77078; 77080-77081; 77085	<ul style="list-style-type: none"> Received one or more osteoporosis screening tests between their 65th birthday and December 31st of the measurement year (2020). <p>Exclusions:</p> <ul style="list-style-type: none"> History of osteoporosis medication therapy Filled prescription for medication to treat osteoporosis

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

Prevention and Screening	
Measure	Screening, test or care needed
<p>*Childhood Immunization</p> <p>Children who turn 2 years old during the measurement year (2020).</p> <p>Vaccines must be completed <u>on or before the 2nd birthday</u></p>	<ul style="list-style-type: none"> • 4 DTaP (do not count any before 42 days of age) • 3 IPV (do not count any before 42 days of age) • 1 MMR • 3 HiB (do not count any before 42 days of age) • 3 Hepatitis B • 1 VZV, positive serology, or documented chicken pox disease • 4 pneumococcal conjugate • 1 Hepatitis A • 2 or 3 Rotavirus vaccines- depends on the vaccine administered (do not count any before 42 days of age) • 2 Influenza with different dates of service. One of the two vaccinations can be an LAIV- live attenuated influenza vaccine- if administered on the child's 2nd birthday. (do not count any given prior to 6 months of age) <p>Documentation of "immunizations are up-to-date" is <u>not</u> acceptable.</p> <p>Documentation of an immunization (such as the first Hep B) received "at delivery" or "in the hospital" may be counted.</p> <p><u>Exclusion:</u> Contraindication for a specific vaccine (e.g., anaphylactic reaction to the vaccine or its components)</p>
<p>*Immunizations for Adolescents</p> <p><u>NOTE:</u> This measure includes the Human Papillomavirus Vaccine (HPV) for <u>both males and females</u>.</p> <p>Children who turn 13 years old during the measurement year (2020).</p> <p><u>CPT Codes:</u> Meningococcal: 90734 Tdap: 90715 HPV: 90649-90651</p>	<ul style="list-style-type: none"> • 1 dose Meningococcal vaccine between the 11th and 13th birthdays <u>and</u> • 1 tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine between the 10th and 13th birthdays <u>and</u> • 2-dose <u>or</u> 3-dose HPV vaccination series between the 9th and 13th birthdays <p><u>NOTE:</u> <u>All</u> vaccines must be completed <u>on or before the 13th birthday</u></p> <p>Documentation of "immunizations are up-to-date" is <u>not</u> acceptable.</p> <p><u>Exclusion:</u> Contraindication for a specific vaccine (e.g., anaphylactic reaction to the vaccine or its components)</p> <p>Parental refusal is <u>not</u> an exclusion</p>
<p>*Lead Screening in Children (Medicaid only)</p> <p>Children who turn 2 years old during the measurement year (2020).</p> <p><u>CPT Code:</u> 83655</p>	<ul style="list-style-type: none"> • At least one capillary or venous lead blood test <u>by their 2nd birthday</u>. <p>Documentation in the record must include <u>both</u> of the following:</p> <ul style="list-style-type: none"> • Date the test was performed • The result or finding

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2020, please contact Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Measure	Screening, test or care needed
<p>*Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents</p> <p>Members 3-17 years of age, who had an outpatient visit with a PCP or OB/GYN during 2020 and had evidence of the following documented:</p> <ul style="list-style-type: none"> • BMI percentile • Counseling for Nutrition • Counseling for Physical Activity <p>ICD-9 Codes: BMI percentile: Z68.51-Z68.54</p> <p>Counseling for nutrition : Z71.3</p> <p>Counseling for physical activity: Z02.5; Z71.82</p> <p>CPT Codes Counseling for nutrition: 97802-97804</p>	<p>Weight and height must be taken during the measurement year (2020).</p> <p>BMI Percentile documentation must include date, height, weight and:</p> <ul style="list-style-type: none"> • BMI percentile (may be plotted on age-growth chart) <p>Counseling for Nutrition documentation must include a note indicating the date and at least one of the following:</p> <ul style="list-style-type: none"> • Discussion of current nutrition behaviors (e.g., eating habits, dieting behaviors) • Checklist indicating nutrition was addressed • Counseling or referral for nutrition education • Member received educational materials on nutrition during a face-to-face visit • Anticipatory guidance for nutrition • Weight or obesity counseling • Referral to WIC <p>Counseling for Physical Activity documentation includes a note indicating the date and at least one of the following:</p> <ul style="list-style-type: none"> • Discussion of current physical activity behaviors (e.g., exercise routine, participation in sports activities, exam for sports participation) • Checklist indicating physical activity was addressed • Counseling or referral for physical activity • Member received educational materials on physical activity during a face-to-face visit • Anticipatory guidance specific to the child's physical activity • Weight or obesity counseling <p>Documentation of meeting Developmental Milestones only does <u>not</u> meet HEDIS[®] criteria for Physical Activity Counseling.</p> <p>Services specific to an acute or chronic condition do <u>not</u> count toward the counseling indicators for either nutrition or physical activity.</p>
<p>*Cervical Cancer Screening Women ages 21-64</p> <p>CPT Codes to identify Cervical Cancer Screening</p> <p>Cervical cytology: 88141-88143; 88147-88148; 88150; 88152-88154; 88164- 88167; 88174-88175</p> <p>HPV tests: 87620-87622; 87624-87625</p>	<ul style="list-style-type: none"> • A PAP test (cervical cytology) within the last 3 years (2018-2020) for women ages 21-64 • Cervical high-risk human papillomavirus (hrHPV) testing within the last 5 years (2016-2020) for women ages 30-64. • Cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last 5 years (2016-2020) for women ages 30-64. <p>Exclusion: Documentation of hysterectomy with <u>no residual cervix</u> is required:</p> <ul style="list-style-type: none"> • "Complete", "total" or "radical hysterectomy (abdominal, vaginal or unspecified)" • "Vaginal hysterectomy" • "Vaginal pap smear" in conjunction with "hysterectomy" • "Hysterectomy" in combination with documentation that member no longer needs pap test/cervical cancer screening <p>Documentation of "hysterectomy" alone does not meet the criteria.</p>

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

Measure	Screening, test or care needed
Non-Recommended Cervical Cancer Screening in Adolescent Females Adolescent females ages 16-20	<ul style="list-style-type: none"> Screened unnecessarily for cervical cancer <p>Note: A lower rate indicates better performance</p> <p>Exclusion: History of cervical cancer, HIV or immunodeficiency</p>
Chlamydia Screening Females ages 16-24 and identified as sexually active (by claims or pharmacy data) CPT Codes for Chlamydia Screening: 87110; 87270; 87320; 87490- 87492; 87810	<ul style="list-style-type: none"> At least one test for Chlamydia during the measurement year (2020). <p>Exclusion: A pregnancy test <i>alone</i> during the measurement year and either:</p> <ul style="list-style-type: none"> A prescription for isotretinoin on the date of the pregnancy test or six days after the pregnancy test. An x-ray on the date of pregnancy test or the six days after the pregnancy test
Breast Cancer Screening Women ages 50-74 CPT Codes to identify Mammography: 77055-77057; 77061-77063; 77065-77067	<ul style="list-style-type: none"> A mammogram (screening, diagnostic, digital or digital breast tomosynthesis) on or between October 1, 2018 -December 31, 2020. <p>NOTE: MRI's, ultrasounds or biopsies <i>alone</i> do not count- a mammogram is also required.</p> <p>Exclusion: Bilateral Mastectomy</p>
Non-recommended PSA-Based Screening in Older Men Men age 70 and older CPT codes for PSA-based Screening: 84152-84154	<ul style="list-style-type: none"> Screened unnecessarily for prostate cancer <p>Exclusions:</p> <ul style="list-style-type: none"> Prostate cancer diagnosis Dysplasia of the prostate A PSA test during the year <i>prior to</i> the measurement year (2019) where laboratory data indicate an elevated result or abnormal finding. Dispensed prescription for a 5-alpha reductase inhibitor during the measurement year (2020).
*Colorectal Cancer Screening Adults ages 50-75 CPT Codes for Colorectal Cancer Screening: <i>FOBT:</i> 82270; 82274 <i>FIT-DNA:</i> 81528 <i>Flexible Sigmoidoscopy:</i> 45330-45335; 45337-45342; 45345-45347; 45349-45350 <i>CT Colonography:</i> 74261-74263 <i>Colonoscopy:</i> 44388-44394; 44397; 44401-44408; 45355; 45378-45393; 45398	<p>One or more of the following screenings:</p> <ul style="list-style-type: none"> Colonoscopy in past 10 years (2011-2020) Flexible sigmoidoscopy in past 5 years (2016-2020) CT Colonography (e.g., virtual colonoscopy) in the past 5 years (2016-2020) FIT-DNA (e.g., Cologuard) test in the past 3 years (2018-2020) Fecal occult blood test (iFOBT or gFOBT) annually (2020) <p>Exclusion: Diagnosis of colorectal cancer or total colectomy.</p>

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2020, please contact Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Use of Services	
Measure	Screening, test or care needed
<p>Well-child Exams in the First 30 Months of Life</p> <p>Children who turned 15 months or 30 months during 2020</p> <p><u>CPT Codes to Identify Well-Child Visits:</u> 99381-99385; 99391-99395; 99461</p> <p><u>ICD-10 Codes:</u> Z00.00-Z00.01; Z00.110-Z00.111; Z00.121; Z00.129; Z00.2; Z00.3; Z00.5; Z76.1-Z76.2</p>	<p>Well-care visits with a PCP/Pediatrician.</p> <p>Two rates are reported:</p> <ul style="list-style-type: none"> Six (6) or more well visits on different dates of service on or before the 15-month birthday Two (2) or more well visits on different dates of service between the child's 15-month birthday plus one day and the 30-month birthday
<p>Child and Adolescent Well-Care Visits</p> <p>Ages 3-21 years</p> <p><u>CPT Codes to Identify Well-Child Visits</u> 99381-99385; 99391-99395; 99461</p> <p><u>ICD-10 Codes:</u> Z00.00-Z00.01; Z00.110-Z00.111; Z00.121; Z00.129; Z00.2; Z00.3; Z00.5; Z76.1-Z76.2</p>	<ul style="list-style-type: none"> At least one (1) comprehensive well-care visit with a PCP or OB/GYN practitioner during the measurement year (2020).
Respiratory Conditions	
<p>Appropriate Testing for Pharyngitis</p> <p>Ages 3 years and older</p> <p><u>ICD-10 Codes to Identify Pharyngitis:</u> J02.0; J02.8-J02.9; J03.00-J03.01; J03.80-J03.81; J03.90-J03.91</p>	<ul style="list-style-type: none"> Diagnosis of pharyngitis Prescribed an antibiotic and <p>Received a group A streptococcus (strep) test in the 7 day period from 3 days <i>prior to</i>, through 3 days <i>after</i>, the prescription date.</p>
<p>Appropriate Treatment for Upper Respiratory Infection</p> <p>Ages 3 months and older</p> <p><u>ICD-10 Codes to identify URI:</u> J00; J06.0; J06.9</p>	<ul style="list-style-type: none"> Diagnosis of Upper Respiratory Infection (URI), <i>and</i> Not prescribed an antibiotic within 3 days of URI diagnosis.
<p>Avoidance of Antibiotic Treatment for Bronchitis/Bronchiolitis</p> <p>Ages 3 months and older</p> <p><u>ICD-10 Codes to identify Acute Bronchitis:</u> J20.3-J20.9; J21.0-J21.1; J21.8-J21.9</p>	<ul style="list-style-type: none"> Diagnosis of acute bronchitis/bronchiolitis, <i>and</i> Not dispensed an antibiotic prescription within 3 days of diagnosis. <p>Exclusion: members with a diagnosis of any of the following comorbid conditions: <input checked="" type="checkbox"/> Emphysema; COPD; Immune system disorder; HIV; Malignant neoplasm</p>

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2020, please contact Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Measure	Screening, test or care needed
Use of Spirometry Testing in the Assessment and Diagnosis of COPD Adults age 40 and older CPT Codes for Spirometry Testing: 94010; 94014-94016; 94060; 94070; 94375; 94620	<ul style="list-style-type: none"> Diagnosis of new, or newly active, COPD between July 1, 2019-June 30, 2020 and Spirometry testing to confirm the diagnosis in the 2 years prior through 6 months after the diagnosis.
Pharmacotherapy Management of COPD Exacerbation Adults age 40 and older ICD-10 Codes to identify COPD: J44.0; J44.1; J44.9	<ul style="list-style-type: none"> Discharged from an acute inpatient admission or an ED visit with a primary diagnosis of COPD on or between January 1 – November 30, 2020 and Dispensed (or already had an active prescription for) both: <ol style="list-style-type: none"> A systemic corticosteroid within 14 days of the event A bronchodilator within 30 days of the event
Cardiovascular	
*Controlling High Blood Pressure Adults ages 18-85 Adequate control is defined as: <140/90 ICD-10 Codes to identify HTN: I10 CPT II Codes for BP values: Systolic Less than 140: 3074F, 3075F Systolic Greater than/Equal to 140: 3077F Diastolic Less than 80: 3078F Diastolic 80-89: 3079F Diastolic Greater than/Equal to 90: 3080F	<ul style="list-style-type: none"> Diagnosis of hypertension Most recent blood pressure reading in the medical record for 2020. Exclusions: Evidence of any of the following during 2020: <ul style="list-style-type: none"> End Stage Renal Disease (ESRD), or dialysis Kidney transplant Pregnancy Nonacute inpatient admission
Statin Therapy for Patients with Cardiovascular Disease Males ages 21-75; Females ages 40-75 Moderate or high-intensity statin therapy: Atorvastatin: 10-80mg Amlodipine-atorvastatin: 10-80mg Rosuvastatin: 5-40mg Simvastatin: 20-80mg Ezetimibe-simvastatin: 20-80mg Pravastatin: 40-80mg Lovastatin: 40mg Fluvastatin 40-80mg Pitavastatin 2-4mg ICD-10 codes for myalgia/myositis/myopathy: G72.0; G72.2; G72.9; M60.80-M60.812; M60.819; M60.821-M60.822; M60.829; M60.831-M60.832; M60.839; M60.841-M60.842; M60.849; M60.851-M60.852; M60.859; M60.861-M60.862; M60.869; M60.871-M60.872; M60.879; M60.88-M60.89; M60.9; M62.82; M79.1-M79.12; M79.18	<ul style="list-style-type: none"> Identified as having clinical atherosclerotic cardiovascular disease (ASCVD) Two rates are reported: <ol style="list-style-type: none"> Received Statin Therapy: Members who were dispensed at least one <i>high or moderate-intensity</i> statin medication during the measurement year (2020). Statin Adherence 80%: Members who remained on a high or moderate-intensity statin medication for at least 80% of the treatment period (from prescription date through end of year). Exclusions: <ul style="list-style-type: none"> Pregnancy/IVF ESRD or dialysis Cirrhosis Myalgia, myositis, myopathy or rhabdomyolysis Dispensed a Dementia medication

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

Diabetes	
Measure	Screening, test or care needed
<p>*Comprehensive Diabetes Care</p> <p>Adults ages 18-75 with diagnosis of diabetes (type 1 <u>or</u> type 2) <u>or</u> who have been prescribed insulin or hypoglycemic/antihyperglycemics.</p> <p>ICD-10 Codes to identify Diabetes: E10.10-E10.9; E11.00-E11.9; E13.00-E13.9</p> <p>CPT II codes for Diabetic retinal Screening: 3072F; 2022F; 2023F; 2024F; 2025F; 2026F; 2033F</p> <p>CPT II Codes for BP values: Systolic Less than 140: 3074F, 3075F Systolic Greater than/Equal to 140: 3077F Diastolic Less than 80: 3078F Diastolic 80-89: 3079F Diastolic Greater than/Equal to 90: 3080F</p>	<ol style="list-style-type: none"> HbA1c testing (most recent date and result from 2020) <ul style="list-style-type: none"> HbA1c < 8.0 % = control HbA1c > 9.0 % = poor control Retinal/dilated eye exam (most recent date and result from 2019 or 2020) or bilateral eye enucleation any time through 2020 Medical attention for nephropathy (one of the following during 2020): <ul style="list-style-type: none"> Nephropathy screening or monitoring test (urine protein) ACE/ARB therapy Evidence of nephropathy (CKD, ESRD, dialysis, nephrectomy, kidney transplant, visit with a nephrologist) Blood pressure (most recent date and result from 2020) <ul style="list-style-type: none"> BP of < 140/90 = control <p>Exclusions: Members without a diagnosis of diabetes in any setting, but did have :</p> <ul style="list-style-type: none"> Gestational diabetes ; Steroid-induced diabetes; <i>or</i> Polycystic ovarian syndrome (during 2019 or 2020)
<p>Statin Therapy for Patients with Diabetes</p> <p>Adults ages 40-75</p> <p>ICD-10 codes for myalgia, myositis, myopathy: G72.0; G72.2; G72.9; M60.80-M60.812; M60.819; M60.821-M60.822; M60.829; M60.831-M60.832; M60.839; M60.841-M60.842; M60.849; M60.851- M60.852; M60.859; M60.861-M60.862; M60.869; M60.871-M60.872; M60.879; M60.88-M60.89; M60.9; M62.82; M79.1-M79.12; M79.18</p>	<ul style="list-style-type: none"> Identified as having diabetes and do not have ASCVD (clinical atherosclerotic cardiovascular disease) who met the following criteria: <p>Two rates are reported:</p> <ol style="list-style-type: none"> Received Statin Therapy: Members who were dispensed at least one statin medication of <i>any intensity</i> during the measurement year (2020). Statin Adherence 80%: Members who remained on a statin medication of any intensity for at least 80% of the treatment period (from prescription date through end of year). <p>Exclusions: Myalgia, myositis, myopathy or rhabdomyolysis (in 2020)</p> <p>Any of the following (in 2019 <u>or</u> 2020): Polycystic ovarian syndrome; Pregnancy/IVF ; Prescribed clomiphene; ESRD or dialysis; Cirrhosis</p>
Musculoskeletal	
<p>Osteoporosis Management in Women who had a Fracture</p> <p>Women ages 67-85</p> <p>CPT Codes to identify BMD test: 76977; 77078; 77080-77081; 77085-77086</p> <p>HCPCS codes for osteoporosis meds: J0897; J1740; J3110; J3489</p>	<p>Suffered a fracture and had one of the following in the 6 months after the fracture:</p> <ul style="list-style-type: none"> Abone mineral density (BMD) test <i>or</i> A prescription for a drug to treat osteoporosis

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Measure	Screening, test or care needed									
<p>Use of Imaging Studies for Low Back Pain</p> <p>Adults ages 18- 50</p> <p><u>ICD-10 Codes to identify Uncomplicated Low Back Pain:</u> M47.26-M47.28; M47.816-M47.898; M48.06-M48.08; M51.16-M51.17; M51.26-M51.87; M53.2X6-M53.2X8-M53.88; M54.16-M54.9; M99.03-M99.84 S33.100A-S33.9XXA; S39.002A-S39.92XS</p>	<ul style="list-style-type: none">Primary diagnosis of low back pain whodid not have an imaging study (x-ray, MRI, CT) within 28 days of the diagnosis. <p>– A <u>higher score</u> indicates <u>appropriate treatment</u> of low back pain</p> <p>Exclusions: An imaging study in the presence of low back pain is considered <u>clinically indicated</u> in patients with a diagnosis of:</p> <table><tr><td>-Cancer</td><td>-Recent Trauma</td><td>-IV Drug Abuse</td></tr><tr><td>-Neurologic Impairment</td><td>-Spinal Infection</td><td>-HIV</td></tr><tr><td>-Major Organ Transplant</td><td>-Prolonged Use of Corticosteroids</td><td></td></tr></table>	-Cancer	-Recent Trauma	-IV Drug Abuse	-Neurologic Impairment	-Spinal Infection	-HIV	-Major Organ Transplant	-Prolonged Use of Corticosteroids	
-Cancer	-Recent Trauma	-IV Drug Abuse								
-Neurologic Impairment	-Spinal Infection	-HIV								
-Major Organ Transplant	-Prolonged Use of Corticosteroids									
Behavioral Health										
<p>Follow-up Care for Children Prescribed ADHD Medication</p> <p>Ages 6-12 years</p>	<ul style="list-style-type: none">An initial prescription for ADHD medication (or first fill in >120 days)Remained on the medicationHad appropriate follow up care visits <p>Two rates are reported:</p> <ol style="list-style-type: none">Initiation Phase:<ul style="list-style-type: none">– one follow-up visit with a prescribing practitioner within 30 daysContinuation and Maintenance Phase:<ul style="list-style-type: none">– remained on the medication for at least 210 days and– had two additional visits with a practitioner within 270 days (9 months after the Initiation Phase ended).									
<p>Metabolic Monitoring for Children and Adolescents on antipsychotics</p> <p>Children/Adolescents ages 1-17</p> <p><u>CPT Codes to identify cholesterol tests other than LDL:</u> 82465; 83718; 83722; 84478</p>	<ul style="list-style-type: none">At least 2 antipsychotic prescriptions (same or different medications) on different dates during the measurement year (2020)Blood glucose <u>or</u> HbA1c test during the measurement year (2020) andLDL-C <u>or</u> cholesterol test during the measurement year (2020)									
<p>Antidepressant Medication Management</p> <p>Adults age 18 and older</p> <p><u>ICD-10 Codes to identify Major Depression:</u> F32.0-F32.4; F32.9; F33.0- F33.3; F33.41; F33.9</p>	<ul style="list-style-type: none">Were treated with antidepressant medicationHad a diagnosis of major depression andRemained on antidepressant medication treatment. <p>Two rates are reported:</p> <ol style="list-style-type: none">Effective acute phase: remained on an antidepressant medication for at least 84 days (12weeks)Effective continuation phase: remained on an antidepressant medication for at least 180 days (6months)									

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Measure	Screening, test or care needed
Adherence to Antipsychotic Medications for Individuals with Schizophrenia Ages 18 and older	<ul style="list-style-type: none"> Diagnosis of Schizophrenia/schizoaffective disorder Dispensed an antipsychotic medication and Remained on the medication for at least 80% of their treatment period (days between the earliest prescription fill in 2020 and the end of the year)
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who are Using Antipsychotic Medications Adults ages 18-64 <u>ICD-10 Codes to identify diagnosis:</u> Bipolar: F30.10-F30.13; F30.2-F30.4; F30.8-F30.9; F31.0; F31.10-F31.13; F31.2; F31.30-F31.32; F31.4-F31.5; F31.60-F31.64; F31.70-F31.78; F31.81; F31.89; F31.9 Schizophrenia: F20.0-F20.3; F20.5; F20.81; F20.89; F20.9; F25.0-F25.1; F25.8-F25.9	<ul style="list-style-type: none"> Diagnosis of Schizophrenia, Schizoaffective Disorder or Bipolar Disorder Dispensed an Antipsychotic medication on an ambulatory basis Diabetes screening (glucose or HbA1c) test during the measurement year (2020) <u>CPT Codes to Identify Diabetes Screening:</u> Glucose tests: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951 HbA1c tests: 83036, 83037
Diabetes Monitoring for People with Diabetes and Schizophrenia Adults ages 18-64	<ul style="list-style-type: none"> Diagnoses of Schizophrenia/schizoaffective disorder and Diabetes HbA1c test during the measurement year (2020) and LDL-C test (direct or calculated) during the measurement year (2020)
Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia Adults ages 18-64	<ul style="list-style-type: none"> Diagnoses of Schizophrenia/schizoaffective disorder and Cardiovascular Disease LDL-C test (direct or calculated) during the measurement year (2020) <u>CPT Codes to Identify LDL-C Screening:</u> 80061; 83700; 83701; 83704; 83721
Follow-Up After Emergency Department visit for Mental Illness Ages 6 and over	<ul style="list-style-type: none"> ED visit with a principal diagnosis of Mental Illness or intentional self-harm Follow-Up visit with any practitioner, with a principal diagnosis of a Mental Health disorder Two rates are reported: <ol style="list-style-type: none"> Follow-up visit within 7 days of discharge Follow-up visit within 30 days of discharge
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Dependence Ages 13 and older	<ul style="list-style-type: none"> ED visit with principal diagnosis of Alcohol or Other Drug (AOD) Abuse/Dependence Follow-Up visit with any practitioner with a principal diagnosis of AOD Two rates are reported: <ol style="list-style-type: none"> Follow-up visit within 7 days of discharge Follow-up visit within 30 days of discharge

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Measure	Screening, test or care needed
Follow-up After Hospitalization for Mental Illness Ages 6 and over	<ul style="list-style-type: none"> Hospitalized for treatment of selected mental illness or intentional self-harm and One follow-up outpatient visit, intensive outpatient encounter, or partial hospitalization with a mental health provider. <p>Two rates are reported:</p> <ol style="list-style-type: none"> Follow-up visit within 7 days of discharge Follow-up visit within 30 days of discharge
Follow-Up After High-Intensity Care for Substance Use Disorder Ages 13 and older	<ul style="list-style-type: none"> Acute inpatient hospitalization, residential treatment or detoxification visit Diagnosis of substance use disorder Follow-up visit or event with any practitioner for a principal diagnosis of substance use disorder <p>Two rates are reported:</p> <ol style="list-style-type: none"> Follow-up within 7 days after the visit or discharge Follow-up within 30 days after the visit or discharge
Pharmacotherapy for Opioid Use Disorder Ages 16 and older	<ul style="list-style-type: none"> Diagnosis of opioid use disorder Dispensed an opioid use disorder treatment medication (e.g., Naltrexone, Buprenorphine) Taken for 180 days
Medication Management and Care Coordination	
Risk of Continued Opioid Use Ages 18 and older	<ul style="list-style-type: none"> A new episode of opioid use that puts them at risk for continued opioid use <p>Two rates are reported:</p> <ol style="list-style-type: none"> The percentage of members with at least 15 days of prescription opioids in a 30-day period The percentage of members with at least 31 days of prescription opioids in a 62-day period <p><u>NOTE:</u> A <i>lower</i> rate indicates better performance.</p>
Use of Opioids at High Dosage Ages 18 and older	<ul style="list-style-type: none"> Received prescription opioids at a high dosage (average morphine milligram equivalent dose [MME] ≥ 90mg) for ≥ 15 days during measurement year (2020) <p><u>NOTE:</u> Reported as the rate per 1,000. A <i>lower</i> rate indicates better performance.</p>

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS[®] MY 2020, please contact Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Measure	Screening, test or care needed
Use of Opioids From Multiple Providers Ages 18 and older	<ul style="list-style-type: none"> Received prescription opioids for ≥ 15 days during 2020 Three rates are reported: Above prescriptions received from and/or filled at: <ul style="list-style-type: none"> Multiple Prescribers (four or more different prescribers) Multiple Pharmacies (four or more different pharmacies) Multiple Prescribers and Multiple Pharmacies (<i>both</i> four or more prescribers <u>and</u> four or more pharmacies)
Follow-Up After ED Visit for People with Multiple High-Risk Chronic Conditions Ages 18 and older	<ul style="list-style-type: none"> ED Visit Multiple (2 or more different) high-risk chronic conditions (e.g., COPD/asthma; dementia; CKD; major depression; heart failure; MI; atrial fibrillation; stroke) Follow-Up service within 7 days of the ED visit
Transitions of Care Adults ages 18 and older <u>CPT codes for Transitional Care Management Services and Medication Reconciliation:</u> 99483, 99495, 99496, 1111F	Documentation in the PCP record of the following in 2020: <ul style="list-style-type: none"> Notification of Inpatient Admission on the day of admission through 2 days after Receipt of Discharge Information on the day of discharge through 2 days after Patient Engagement After Inpatient Discharge (e.g., office visits, home visits, telehealth) provided within 30 days after discharge Medication Reconciliation conducted by a prescribing practitioner, clinical pharmacist or registered nurse on the date of discharge through 30 days after discharge (documentation of review of <u>both</u> a list of the member's current outpatient medications and the discharge medications, or notation that no medications were prescribed upon discharge).
Potentially Harmful Drug- Disease Interactions in Older Adults Ages 65 and older	<ul style="list-style-type: none"> Evidence of an underlying disease, condition or health concern Dispensed an ambulatory prescription for a potentially harmful medication, concurrent with or after the diagnosis <p>Three rates are reported:</p> <ol style="list-style-type: none"> A history of falls and a prescription for antiepileptics, antipsychotics, benzodiazepines, non-benzodiazepine hypnotics, or antidepressants (SSRI's, tricyclic antidepressants, SNRI's) Dementia and a prescription for antipsychotics, benzodiazepines, non-benzodiazepine hypnotics, tricyclic antidepressants, or anticholinergic agents. Chronic kidney disease and a prescription for Cox-2 Selective NSAIDs or non-aspirin NSAIDs <p>NOTE: A lower rate represents better performance for all rates.</p>

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Measure	Screening, test or care needed
Use of High-Risk Medications in Older Adults Ages 66 and older	<ul style="list-style-type: none"> Received at least two dispensing events for high-risk medications to avoid from the same drug class (except for appropriate diagnoses). <p>NOTE: A lower rate represents better performance.</p>
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics Ages 1-17 years Codes to identify psychosocial care: CPT: 90832-90834; 90836-90840; 90845-90847; 90849; 90853; 90875-90876; 90880	<ul style="list-style-type: none"> A new prescription (4 month negative medication history) for an antipsychotic medication Documentation of psychosocial care as first-line treatment during the period from 90 days prior to 30 days after the prescription fill. <p>Exclusions:</p> <ul style="list-style-type: none"> At least one acute inpatient encounter, or at least 2 visits in an outpatient, intensive outpatient or partial hospitalization setting with a diagnosis of <i>schizophrenia, schizoaffective disorder, bipolar disorder, other psychotic disorder, autism, or other developmental disorder</i> during the measurement year (2020)
Adult Access to Preventive/Ambulatory Health Services Adults age 20 and over	<ul style="list-style-type: none"> An ambulatory or preventive care visit <ul style="list-style-type: none"> in the measurement year (2020) for Medicaid and Medicare members in the measurement year or two years prior (2018-2020) for Commercial members
*Prenatal/Postpartum Care Pregnant Women who delivered a live infant between <u>October 8, 2019 and October 7, 2020</u>	<ul style="list-style-type: none"> Prenatal visit within first trimester (on or before the enrollment start date or within 42 days of enrollment) Postpartum visit on or between 7 and 84 days after delivery
Prenatal Immunization Status Deliveries in the measurement year (2020)	<p>Received recommended vaccines:</p> <ul style="list-style-type: none"> Influenza (between July 1, 2019 and delivery date in 2020) Tetanus, diphtheria toxoids and acellular pertussis (Tdap) during the pregnancy (including on the delivery date)
Initiation and Engagement of Alcohol and Other Drug Dependence (AOD) Treatment Ages 13 and older Codes to identify AOD visits: 98960- 98962; 99078; 99201-99205; 99211-99215; 99241-99245; 99341-99345; 99347-99350; 99384-99387; 99394-99397; 99401-99404; 99408-99409; 99411-99412; 99483; 99510	<p>A new episode (60 days negative diagnosis history) of alcohol or other drug (AOD) abuse or dependence</p> <ul style="list-style-type: none"> Initiate treatment within 14 days of the diagnosis through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth, or medication-assisted treatment (MAT) Receive at least 2 additional AOD services or MAT within 34 days of the initiation visit

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Measure	Screening, test or care needed
Measures Collected through CAHPS Survey (Consumer Assessment of Healthcare Providers and Systems)	
Medical Assistance with Smoking Cessation Current Smoker/Tobacco user ages 18 and older	<ul style="list-style-type: none"> Received <u>advice to quit</u> during the measurement year (2020). Discussed or were <u>recommended cessation medications</u> during the measurement year (2020). Discussed or were <u>provided cessation methods or strategies</u> during the measurement year (2020).
Flu Vaccinations for Adults (ages 18-64) Flu Vaccinations for Adults (ages 65+)	Received an influenza vaccination after July 1, 2020 .
Pneumococcal Vaccination Status for Older Adults Ages 65 and older	<ul style="list-style-type: none"> Have <u>ever received</u> one or more pneumococcal vaccinations
Measures Collected through Medicare Health Outcomes Survey (HOS)	
Fall Risk Management Adults ages 65 and older	<ol style="list-style-type: none"> Discussing Fall Risk <ul style="list-style-type: none"> Seen by a practitioner in the past 12 months <u>Discussed</u> falls or problems with balance or walking with their current practitioner Managing Fall Risk <ul style="list-style-type: none"> Had a fall or problems with balance or walking in the past 12 months Seen by a practitioner in the past 12 months Received a <u>recommendation</u> for how to prevent falls or treat problems with balance or walking from their current practitioner
Management of Urinary Incontinence in Older Adults Adults ages 65 and older	<ol style="list-style-type: none"> Discussing Urinary Incontinence <ul style="list-style-type: none"> Reported having urine leakage in the past 6 months <u>Discussed their urinary leakage</u> problem with a healthcare provider Discussing Treatment of Urinary Incontinence <ul style="list-style-type: none"> Reported having urine leakage in the past 6 months <u>Discussed treatment options</u> for their current urine leakage problem Impact of Urinary Incontinence <ul style="list-style-type: none"> Reported having urine leakage in the past 6 months Reported that urine leakage made them change their daily activities or interfered with their sleep a lot.
Physical Activity in Older Adults Adults ages 65 and older	Had a doctor's visit in the past 12 months <ol style="list-style-type: none"> Discussing Physical Activity: Spoke with a doctor or other health provider about their level of exercise or physical activity Advising Physical Activity: Received advice to start, increase or maintain their level of exercise or physical activity

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Measures Collected through Electronic Clinical Data Systems (ECDS)

Measure	Screening, test or care needed
Adult Immunization Status Adults 19 years of age and older CPT Codes: Influenza: 90655; 90657; 90661; 90673; 90685- 90689 Td or Tdap: 90714-91705; 90718 Zoster: 90736 Pneumococcal: 90732	Received recommended routine vaccines: <ul style="list-style-type: none"> Influenza vaccine on or between July 1, 2019 - June 30, 2020 Td or Tdap on or between January 1, 2011-December 31, 2020 Zoster (one dose of herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine, at least 28 days apart) anytime on or after the member's 50th birthday Pneumococcal vaccine on or after the member's 60th birthday
Depression Screening and Follow-Up for Adolescents and Adults Ages 12 years and older	<ul style="list-style-type: none"> Screened for depression using a standardized tool If screening was positive, received follow-up care within 30 days (e.g., an outpatient or telephone follow-up visit; a depression case management encounter; a behavioral health encounter; dispensed antidepressant medication)
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults Ages 12 and older <u>ICD-10 Codes to identify Major Depression and Dysthymia:</u> F32.0-F32.5; F32.9; F33.0-F33.3; F43.40-F43.42; F33.9; F34.1 <u>CPT Codes to identify Interactive Outpatient Encounters:</u> 90791; 90792; 90832; 90834; 90837; 98960-98962; 99078; 99201-99205; 99211-99215; 99217-99220; 99241-99245; 99341-99345; 99347-99350; 99381-99387; 99391-99397; 99401-99404; 99411-99412; 99483; 99510 <u>LOINC Codes to identify PHQ administered:</u> 44261-6; 89204-2	<ul style="list-style-type: none"> Diagnosis of major depression or dysthymia Had a PHQ-9 or PHQ-A tool administered during an outpatient encounter at least once during a four-month period <p>Two rates are reported:</p> <ol style="list-style-type: none"> Inclusion in ECDS Rate: The percentage of members 12 and older with a diagnosis of major depression or dysthymia, who are included in an electronic clinical data system (ECDS). Utilization of PHQ-9 Rate: The percentage of PHQ utilization. Members with a diagnosis of major depression or dysthymia who are covered by an ECDS and, if they had an outpatient encounter, have a PHQ-9 score present in their record. <p>Exclusions: Bipolar disorder; Personality disorder; Psychotic disorder, Pervasive Developmental disorder</p>
Depression Remission or Response for Adolescents and Adults Ages 12 and older <u>ICD-10 Codes to identify Major Depression and Dysthymia:</u> F32.0-F32.5; F32.9; F33.0-F33.3; F43.40-F43.42; F33.9; F34.1 <u>CPT Codes to identify Interactive Outpatient Encounters:</u> 90791; 90792; 90832; 90834; 90837; 98960-98962; 99078; 99201-99205; 99211-99215; 99217-99220; 99241-99245; 99341-99345; 99347-99350; 99381-99387; 99391-99397; 99401-99404; 99411-99412; 99483; 99510	<ul style="list-style-type: none"> Diagnosis of major depression or dysthymia An elevated PHQ-9 (total score >9) Evidence of response or remission within 4-8 months of the elevated score <p>Four rates are reported:</p> <ol style="list-style-type: none"> ECDS Coverage: Health plan can receive any electronic clinical quality data Follow-Up PHQ-9 within 4-8 months of the elevated score Depression Remission: PHQ-9 score of <5 Depression Response: a PHQ-9 score reduction of at least 50% <p>Exclusions: Bipolar disorder; Personality disorder; Psychotic disorder, Pervasive Developmental disorder</p>

¹ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA)

Measure	Screening, test or care needed
Prenatal Immunization Status	<p>Deliveries during the measurement year (2020) and received the following vaccinations:</p> <ul style="list-style-type: none"> • Influenza vaccine on or between July 1, 2019 and the delivery date. • Tdap vaccine during the pregnancy (including on the delivery date).
Prenatal Depression Screening and Follow-Up	<p>Screened for clinical depression while pregnant. If screening is positive, received follow-up care.</p> <p>Two rates are reported:</p> <ul style="list-style-type: none"> • <i>Depression Screening</i>: Screened for clinical depression during pregnancy using a standardized instrument. • <i>Follow-up on Positive Screen</i>: Received follow-up care within 30 days of a positive depression screening finding.
Postpartum Depression Screening and Follow-Up	<p>Screened for clinical depression postpartum. If screening is positive, received follow-up care.</p> <p>Two rates are reported:</p> <ul style="list-style-type: none"> • <i>Depression Screening</i>: Screened for clinical depression using a standardized instrument during the postpartum period (7-84 days following date of delivery). • <i>Follow-up on Positive Screen</i>: Received follow-up care within 30 days of a positive depression screen finding.
Unhealthy Alcohol Use Screening and Follow-Up Adults age 18 and older	<ul style="list-style-type: none"> • Screened for unhealthy alcohol use <u>using a standardized tool</u> (AUDIT, Single-Question Screen) • If screening was positive, received brief counseling or other follow-up care within 2 months (e.g., feedback on alcohol use and harms; identification of high-risk situations for drinking and coping strategies; development of a personal plan to reduce drinking; documentation of receiving alcohol misuse treatment).

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2020, please contact Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015